Extension Study of JR-051 for Patients with Fabry Disease
Latest Information Update: 08 Dec 2021
At a glance
- Drugs Agalsidase beta (Primary)
- Indications Fabry's disease
- Focus Adverse reactions; Registrational; Therapeutic Use
- Sponsors JCR Pharmaceuticals
- 17 Jun 2020 Results presented in a JCR Pharmaceuticals media release.
- 01 May 2020 Primary endpoint has been met. (Change in plasma GL-3 levels from baseline to week 26), according to results published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders.
- 01 May 2020 Results published in the electronic edition of Molecular Genetics and Metabolism, the official journal of Society for Inherited Metabolic Disorders.